amimestrocel (hUC-MSC PLEB001) / Platinumlife Biotech - LARVOL DELTA

Mesenchymal stem cells for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: A multicenter, single-arm, pivotal clinical Trial (ASH 2025) - "This study suggests the efficacy and good tolerance of hUC-MSC PLEB001 in SR-GI-aGVHD patients, basedon which hUC-MSC PLEB001 (Amimestrocel) became the first approved MSC product by Chinese NMPA."

Clinical • Immunology

MSC-DKD-001: Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Chinese PLA General Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetic Nephropathy • Nephrology • Renal Disease

MSC-AKI-001: Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Chinese PLA General Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Kidney Injury • Nephrology • Renal Disease

MSC-DKD-001: Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Chinese PLA General Hospital

New P2 trial • Diabetic Nephropathy • Nephrology • Renal Disease

MSC-AKI-001: Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury (clinicaltrials.gov) - P2 | N=50 | Not yet recruiting | Sponsor: Chinese PLA General Hospital

New P2 trial • Acute Kidney Injury • Nephrology • Renal Disease